Gain Therapeutics, Inc. (GANX), a clinical-stage biotechnology company, announced promising results on Thursday from its Phase 1 study assessing the safety, tolerability, and pharmacokinetics of GT-02287, an innovative GCase-targeting small molecule therapy aimed at treating Parkinson’s Disease.In an earlier announcement, the company confirmed that there were no discontinuations or serious adverse events reported upon the study’s completion.GT-02287, Gain Therapeutics’ leading drug candidate, is under clinical development for Parkinson’s Disease, regardless of the presence of a GBA1 mutation.The Phase 1 trial included 72 healthy volunteers, both male and female, up to the age of 64 years. A review of the unblinded data after database lock indicated that single and multiple doses of GT-02287 were safe and generally well-tolerated up to the highest planned doses across all age groups.Moreover, GT-02287 was detected in the cerebrospinal fluid (CSF), and peripheral target engagement was demonstrated.Jonas Hannestad, Chief Medical Officer of Gain Therapeutics, stated, “Given this data, we plan to initiate a trial involving Parkinson’s disease patients by Q4 2024, with the aim of demonstrating safety and tolerability in this patient population and obtaining proof of mechanism through relevant biomarkers. We expect to have data from Parkinson’s disease patients by mid-2025.”On Nasdaq, Gain Therapeutics shares were trading at $1.20, a decline of 9.8 percent.The material has been provided by InstaForex Company – www.instaforex.com
- Taiwan Shares Tipped To Open To The Upside - September 15, 2024
- Singapore Bourse Poised To Add To Its Winnings - September 15, 2024
- South Korea Trade Data Due On Monday - September 15, 2024
